China Resources Pharmaceutical Group Limited

Equities

3320

HK0000311099

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:09:09 2024-04-25 am EDT 5-day change 1st Jan Change
4.96 HKD +1.64% Intraday chart for China Resources Pharmaceutical Group Limited +4.20% -3.31%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
China Resources Pharmaceutical Group Limited Announces Change of Company Secretary CI
China Resources Pharma Unit Issues 3 Billion Yuan Bonds MT
China Resources Dong-E-E-Jiao Company Limited Provides Earnings Guidance for the Three Months Ended 31 March 2024 CI
China Resources Pharmaceutical Posts Gains in Full Year 2023 Profit MT
China Resources Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 19 July 2024 CI
China Resources Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
CR Boya Bio-Pharmaceutical's 2023 Profit Falls on Lower Revenue MT
Nomura Adjusts CR Pharmaceutical Group’s Price Target to HK$8.80 From HK$9.08, Keeps at Buy MT
CR Sanjiu Expects Increase in 2023 Profit MT
China Resources Pharmaceutical Unit Completes Capital Increase; Shares Fall 3% MT
China Resources Pharmaceutical Unit Enters Share Subscription Deals to Boost Capital MT
China Resources Pharmaceutical Group Limited Announces Management Changes, Effective on 27 December 2023 CI
China Resources Pharma Unit Boosts Stake in Jiangzhong Pharma Parent MT
China Resources Pharmaceutical Subsidiary Begins Bidding for Potential Share Issuance MT
China Resources Pharmaceutical Group Subsidiary Records Rise in Nine-Month Attributable Profit MT
Dong-E-E-Jiao's Nine-Moth Profit Rises on Higher Revenue MT
CR Boya Bio-Pharmaceutical's January-September Profit Increases MT
Dong-E-E-Jiao Expects January-September Attributable Profit to Rise Up to 60% MT
China Resources Pharma's Profit Marginally Rises in H1 MT
China Resources Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
CR Sanjiu Medical & Pharmaceutical's H1 Attributable Profit Rises 31% MT
KPC Pharmaceuticals' Attributable Profit Rises 3.1%; Shares Slip 4% MT
China Resources Pharmaceutical's Subsidiaries Log Increases in H1 Profits MT
China Resources Boya's H1 Attributable Profit Jumps 16.9% MT
Dong-E-E-Jiao's H1 Attributable Profit Surges 72% MT
Chart China Resources Pharmaceutical Group Limited
More charts
CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED is a Hongkong-based investment holding company. The Company, along with its subsidiaries, is principally engaged in the research and development, manufacturing, distribution and retail of pharmaceutical and other healthcare products. The Company mainly operates through three segments. Pharmaceutical Manufacturing segment is engaged in the research and development, manufacturing and sale of pharmaceutical and other healthcare products. Pharmaceutical Distribution segment is engaged in the provision of distribution solutions to pharmaceutical manufacturers and dispensers, such as hospitals and other medical institutions, distributors and retail pharmacies. Pharmaceutical Retail segment is involved in the operation of retail pharmacies in China and Hongkong.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.96 HKD
Average target price
7.406 HKD
Spread / Average Target
+49.31%
Consensus
  1. Stock Market
  2. Equities
  3. 3320 Stock
  4. News China Resources Pharmaceutical Group Limited
  5. China Resources Pharmaceutical : Dong-E-E-Jiao Swings to Profit in Q1; Shares Rally 4%